Table 2.
Demographic and clinical characteristics among all 5 phenotypes and in the “Non-classified” group
| Characteristics n (wt%) |
AwObesity n = 339 |
B-Eos-high n = 237 |
B-Eos&FeNO-low n = 157 |
FeNO-high n = 110 |
AwCOPD n = 57 |
Non-classified†† n = 77 |
|---|---|---|---|---|---|---|
| Female gender | 366 (67) | 196 (55) | 138 (78) | 78 (52) | 71 (58) | 44 (56) |
| Age (yrs), median (Q1–Q3) | 48.0 (34.0–59.0) | 47.0 (31.0–59.0) | 41.0 (27.0–57.0) | 45.0 (30.0–54.0) | 61.0 (52.0–69.0) | 39.0 (28.0–53.0) |
| BMI (kg/m2), median (Q1–Q3) | 35.4 (32.5–40.4) | 30.3 (25.9–36.8) | 28.9 (24.2–33.0) | 27.6 (24.9–33.4) | 30.3 (25.1–35.1) | 24.3 (22.8–27.5) |
| Race and/or ethnicity | ||||||
| Hispanic | 94 (9) | 78 (11) | 30 (8) | 29 (10) | 18 (4) | 11 (6) |
| Non-Hispanic white | 230 (65) | 175 (73) | 79 (69) | 65 (75) | 80 (81) | 50 (86) |
| Non-Hispanic black | 177 (21) | 74 (12) | 62 (17) | 38 (13) | 27 (11) | 10 (6) |
| Other race | 25 (5) | 21 (4) | 13 (6) | 6 (2) | 10 (4) | 6 (2) |
| Smoking status | ||||||
| Current smoker | 150 (27) | 104 (32) | 48 (23) | 18 (13) | 65 (52) | 23 (28) |
| Ex-smoker | 134 (27) | 100 (32) | 35 (25) | 42 (39) | 70 (48) | 18 (30) |
| Non-smoker | 229 (45) | 124 (35) | 88 (51) | 66 (49) | 0 (0) | 36 (42) |
| Education | ||||||
| ≥ High school | 358 (79) | 227 (80) | 125 (81) | 102 (87) | 73 (59) | 64 (91) |
| Asthma-related medication‡ | ||||||
| Reliever medication** | 234 (42) | 172 (51) | 82 (44) | 65 (46) | 69 (57) | 31 (36) |
| Oral corticosteroids | 36 (5) | 17 (5) | 4 (2) | 10 (7) | 15 (7) | 2 (2) |
| Inhaled corticosteroids§ | 144 (27) | 103 (32) | 36 (20) | 36 (33) | 60 (47) | 17 (19) |
| Asthma-related outcomes | ||||||
| Asthma attack | 363 (68) | 252 (74) | 125 (68) | 98 (71) | 85 (63) | 54 (75) |
| Asthma-related ED | 130 (27) | 80 (23) | 41 (23) | 26 (13) | 37 (32) | 9 (8) |
| > 2 asthma symptoms | 311 (66) | 199 (65) | 92 (55) | 80 (57) | 90 (74) | 42 (59) |
| Work/school absenteeism | 66 (18) | 43 (16) | 25 (18) | 23 (14) | 12 (20) | 10 (14) |
| Lung function | ||||||
| FEV1% predicted, median (Q1–Q3) | 89.0 (75.6–99.2) | 84.1 (75.2–95.4) | 93.2 (83.8–100.8) | 82.7 (75.9–95.4) | 74.0 (62.9–90.1) | 89.9 (80.5–103.5) |
| FEV1/FVC, median (Q1–Q3) | 0.77 (0.62–0.82) | 0.74 (0.65–0.80) | 0.79 (0.72–0.83) | 0.72 (0.66–0.79) | 0.63 (0.50–0.75) | 0.76 (0.69–0.82) |
Data presented as absolute numbers and proportions weighted for the U.S. population
Yrs years, BMI body mass index, Q1 first quartile, Q3 third quartile, BMI body mass index, AwObesity Asthma with obesity, AwCOPD Asthma with concurrent (COPD), ED emergency-department, FEV1 Forced expiratory volume in 1 s, FEV1/FVC forced expiratory volume in 1 s and functional vital capacity ratio, LLN lower limit of normality
††Subjects with non-single and non-multiple asthma phenotype
‡Prescribed medication taken in the past 30 days
** Short-acting β2-agonist and/or anticholinergic
§Alone or in combination with long-acting inhaled β2-agonist